Study to Assess the Safety of Nivolumab in the Treatment of Metastatic Melanoma, Lung Cancer, Renal Cancer, Squamous Cell Carcinoma of the Head and Neck, and Chronic Hodgkin Lymphoma in Adults in Mexico
This is a post-marketing study of patients who started nivolumab as first- or second-line therapy for metastatic melanoma or as second-line therapy for metastatic squamous non-small cell lung cancer (SqNSCLC) , metastatic non-SqNSCLC, metastatic renal cell carcimona (RCC), or recurrent or metastatic squamous cell carcinoma of the head and neck cancer (SCCHN), or third-line therapy for classical Hodgkin lymphoma (cHL) in Mexico.
Multiple Indications Cancer
OTHER: Non-Interventional
Incidence of subjects who report on-study Adverse Events(AEs), approximately 24 months|incidence of subjects who report on-study Serious Adverse Events(SAEs), approximately 24 months
Distribution of on-study AEs, approximately 24 months|Distribution of on-study SAEs, approximately 24 months|Distribution of drug-related AEs, approximately 24 months|Distribution of drug-related SAEs, approximately 24 months|Distribution of AEs leading to discontinuation, approximately 24 months|Distribution of SAEs leading to discontinuation, approximately 24 months|Distribution of age in patients, At Baseline|Distribution of gender in patients, At Baseline|Distribution of tumor history in patients, At Baseline
This is a post-marketing study of patients who started nivolumab as first- or second-line therapy for metastatic melanoma or as second-line therapy for metastatic squamous non-small cell lung cancer (SqNSCLC) , metastatic non-SqNSCLC, metastatic renal cell carcimona (RCC), or recurrent or metastatic squamous cell carcinoma of the head and neck cancer (SCCHN), or third-line therapy for classical Hodgkin lymphoma (cHL) in Mexico.